StockData
Skye Bioscience, Inc. logo

Skye Bioscience, Inc. (SKYE) stock

SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 3/30
$1.00−0.06 (-6.10%)

Close on Nov 17, 2026Market cap $35.42MP/E –Yield –

Skye Bioscience pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Skye Bioscience's pe ratio was 5.5× on Jul 31, 2020.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2020Jul 31, 20205.5×–

More Skye Bioscience figures

See a number that looks wrong?